Filing Summary
Registrant: Eliem Therapeutics, Inc. (the request metadata identifies Climb Bio, Inc.; the filing itself names Eliem Therapeutics, Inc.)
Form 8-K date: January 19, 2023; filed January 24, 2023. The filing reports a board resignation and committee changes under Item 5.02.
Business Context and Reporting Period
The filing does not provide operating or financial-period results. It concerns corporate governance and board composition.
Financial and Liquidity Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes
- Leone Patterson resigned from the Board of Directors effective January 19, 2023.
- Ms. Patterson did not cite disagreement with the company’s operations, policies, or practices.
- The Board reduced its authorized size from seven directors to six.
- The Audit Committee was reconstituted with Adam Rosenberg as chair and Simon Tate and Judith Dunn as members.
- The Nominating and Corporate Governance Committee was reconstituted with Simon Tate as chair and Liam Ratcliffe as a member.
- The Board determined that all Audit Committee members satisfy applicable Nasdaq and Exchange Act requirements, and that Mr. Rosenberg qualifies as an audit committee financial expert.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, business outlook, risk update, contingency, compensation arrangement, or unusual financial item is disclosed. The principal governance-related change is the immediate resignation of a director and resulting committee reconfiguration.
Key Facts to Verify
- Confirm the registrant identity, because the supplied metadata names Climb Bio, Inc., while the filing identifies Eliem Therapeutics, Inc.
- Verify the effective date of Leone Patterson’s resignation and the resulting six-member board authorization.
- Verify the revised membership and chairmanship of the Audit Committee and Nominating and Corporate Governance Committee.
- Confirm Adam Rosenberg’s audit committee financial expert designation and the committee members’ independence under applicable requirements.